Head and neck cancer (HNC) represents a significant global health challenge, characterized by aggressive local invasion, frequent recurrence, and poor survival rates. Beyond its physical burden, HNC ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

Explore cancer drug resistance and its significant impact on treatment options and patient outcomes in modern cancer therapy.

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME). Their anti-tumor functions include recognizing tumor-associated antigens, ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody ...